Ophthalmic Solution pH Control and Preservative Partitioning

Sterile aqueous ophthalmic formulations containing pilocarpine hydrochloride or pilocarpine nitrate at 1.0–4.0% w/v are compounded for intraocular pressure reduction in canine and feline glaucoma. The API is dissolved in Water for Injection after buffer equilibration at pH 4.0–5.5, and tonicity is maintained at 250–350 mOsm/kg with sodium chloride or boric acid. Multi-dose presentations require antimicrobial preservation validated per USP <51>; benzalkonium chloride is retained at 0.004–0.01% w/v when used, and edetate disodium at 0.01% w/v is added to chelate trace metals. Prolonged exposure to pH values above 5.5 opens the lactone ring of pilocarpine to pilocarpic acid; therefore terminal sterilisation at 121°C for 15 minutes is restricted to solutions buffered below 5.0. In production vessels of 316L stainless steel with dimpled jacket and bottom-mounted agitator, bulk solution is mixed at 50–100 rpm under nitrogen overlay. Sterile filtration through 0.22 µm PVDF or PES membrane capsules is preferred when pH exceeds 5.0, and filtrate is collected in a separate validated receiver before blow-fill-seal or pre-sterilised dropper bottle filling. Finished ophthalmic solution is tested for particulate matter per USP <789>, sterility per USP <71>, bacterial endotoxins per USP <85>, pH per USP <791>, and osmolality per USP <785>. A common batch failure on high-speed dropper lines is subvisible particle formation caused by pH drift during autoclaving; in-process pH stability monitoring is therefore run before and after hold times of 24–48 hours at 25°C and 40°C.

Filling equipment intended for ophthalmic solutions must maintain laminar flow at ISO Class 5 under EU GMP Annex 1 and 21 CFR Part 211. Multiple-use dropper bottles made of low-density polyethylene are leak-tested at −0.2 bar vacuum, and the preservative efficacy is assessed according to USP <51> category 1 criteria. The most significant process bottleneck is the low preservative concentration combined with the amine nature of pilocarpine, which can bind to filter membranes; filter compatibility studies using 0.22 µm PVDF at 1.0–4.0% w/v API concentration are required prior to scaling from laboratory to production. Assay loss at the membrane can be limited by pre-rinsing with 1–2 L/m² of filtered vehicle, but no more than 0.5% of the nominal API is permitted in the rinse for batch accountability.

How Are Low-Dose Veterinary Oral Solids Maintained Within USP <711> Dissolution Limits?

Pilocarpine hydrochloride tablets for feline and canine lacrimal and salivary support are direct-compressed or wet-granulated at strengths of 1.25 mg, 2.5 mg, and 5.0 mg per unit in a total core weight of 80–120 mg. Because the active mass is less than 5% of the core, geometric dilution with spray-dried lactose monohydrate or microcrystalline cellulose is required before high-shear mixing in a 300 L bin blender or 100 L high-shear granulator. Blend uniformity testing follows USP <905> with 10 sampling points and an acceptance value not exceeding 15; failures typically originate when API particles of D90 > 75 µm segregate from coarse excipients during discharge. Tablets compressed on a 10-station rotary press at 5–12 kN and 20–40 rpm achieve 30–70 N crushing strength for 6 mm concave tooling. Dissolution testing under USP <711> Apparatus II at 50 rpm in 500 mL of pH 1.2 simulated gastric fluid at 37.0±0.5°C is used for release; sustained release should not be assumed because pilocarpine is water-soluble and can release rapidly unless formulated with rate-controlling polymers such as hypromellose. Capsules are filled by tamping pin machines with lactose and magnesium stearate 0.5%; empty capsule mass variation is controlled to ±3%. Moisture is a critical variable because pilocarpine hydrochloride is hygroscopic; packages are sealed with desiccant canisters and bulk hold rooms are maintained below 40% RH at 20–25°C.

Compliance for veterinary oral solids is assessed against 21 CFR Part 211, with release testing including identity by HPLC against USP pilocarpine hydrochloride RS, assay per the USP monograph, dissolution per USP <711>, content uniformity per USP <905>, and microbial enumeration per USP <61> and USP <62>. The principal operational boundary is that dry blending must not be extended beyond 25 minutes because electrostatic charge increases and blend uniformity degrades; where granulation is required, aqueous granulation is conducted with binder solution adjusted to pH 4.0–5.0, and the wet mass is milled through 850 µm screens before fluid bed drying at inlet air 55–65°C to LOD ≤ 1.5%. Published data for specific veterinary dissolution specifications is limited, so laboratories often qualify in-house limits using pilot batches and similarity evaluation where a comparator exists.

In compounded veterinary injectables, pilocarpine hydrochloride is prepared as a sterile solution at 0.1–5.0 mg/mL in Water for Injection. The solution is adjusted to pH 4.0–5.0 with hydrochloric acid or sodium hydroxide, sparged with nitrogen, and filtered through 0.22 µm PVDF membranes into depyrogenated Type I glass vials. Dry heat depyrogenation of vials is performed in a tunnel at 250°C for 45 minutes, while rubber stoppers are steam-sterilised at 121°C for 30 minutes. Terminal autoclaving of the filled solution is generally avoided above pH 5.0 due to lactone hydrolysis to pilocarpic acid, and aseptic filtration is the more reproducible route for animal-use preparations. Release testing includes sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788> by light obscuration, and pH per USP <791>. Endotoxin limits are calculated from the maximum dose per kg and route rather than a fixed specification; a commonly cited control point for parenteral water is 0.25 EU/mL. The main batch failure on aseptic lines is pre-filter pressure increase above 1.0 bar caused by membrane binding of the API, which is managed by membrane selection and not by raising pressure beyond filter manufacturer limits. Published data for licensed veterinary pilocarpine injectables is limited; most formulations are compounded under USP <797> or analogous regional sterile compounding chapters.

The product must be protected from light because pilocarpine undergoes photolytic degradation; amber vials or light-shielded filling lines are used. Post-fill inspection includes container closure integrity testing by vacuum decay per USP <1207> and 100% visual inspection. Any solution exposed to pH above 6.0 during compounding must be discarded or re-assayed because the degradation product pilocarpic acid does not possess the same cholinergic activity and may fail HPLC purity criteria.

When Dry Powder Blends Approach 0.5 mg/g Assay, Segregation Control Becomes Critical

Powder and granule formats for oral administration are produced for compounding pharmacies and for later reconstitution into oral solutions or medicated drinking water. Pilocarpine hydrochloride is initially triturated with lactose monohydrate or dextrose in a low-shear V-blender at 60–80% fill volume and 10–20 rpm; silicon dioxide is added as glidant at 0.1–0.5% w/w and sieved through 500 µm or 850 µm screens before blending. If the nominal active content approaches 0.5 mg/g, blend uniformity failure becomes the dominant risk because API particles settle during hopper discharge and automatic powder dispensing machines may generate assay variance exceeding 10% RSD. Samples for content uniformity are taken at 10 discrete locations and analysed per USP <905>; an acceptance value above 15 triggers re-blending in 10-minute increments. Final powder is dried in a fluid bed dryer with inlet air 55–65°C to loss on drying ≤ 1.5% per USP <731>. Granules produced by high-shear granulation with binder solution adjusted to pH 4.0–5.0 are milled through 850 µm screens and dosed into HDPE bottles or single-dose sachets. The principal operational boundary is incompatibility with alkaline excipients such as sodium carbonate or disodium phosphate above pH 6.0, which accelerates lactone ring hydrolysis during wet massing.

Medicated feed premix operations require validated cleanout because pilocarpine is a potent parasympathomimetic and carryover into non-target species must be limited. Swab sampling after cleaning is quantified by HPLC with a limit not exceeding 10 ppm of the next batch nominal active. Moisture ingress during storage is controlled by desiccant and sealed packaging; stored powder at 25°C and 60% RH is stability-tested for 12–24 months under ICH Q1A conditions. Published data for specific veterinary premix approvals is limited, but the same blending principles apply from human compounding and veterinary pharmacy practice.

Aqueous oral solutions for small animals are compounded at 1–5 mg/mL pilocarpine hydrochloride with citrate or acetate buffer at pH 4.0–5.0 to retain solubility and slow hydrolytic degradation. Sodium benzoate or potassium sorbate at 0.1% w/v provides preservation in multi-dose bottles, and sucrose or sorbitol may be included up to 20% w/v as a taste-masking vehicle. The solution is filtered through 10 µm clarifier cartridges and filled into amber PET bottles at 200–500 bottles/min; viscosity must remain below 5 mPa·s to avoid pump cavitation and inconsistent fill volumes. Photostability of the final package is assessed under ICH Q1B, and the product is stored at 15–25°C with air-conditioned warehouse monitoring. The carrying medium is selected to avoid calcium carbonate antacids because pH rise above 6.0 increases pilocarpic acid formation; therefore label instructions should state separation from alkaline feeds or mineral supplements. Published stability data for veterinary oral pilocarpine solutions under accelerated 40°C/75% RH conditions is limited, so ongoing real-time stability batches are held in quantities of at least 3 lots.